Halozyme Therapeutics (HALO) beats street on Q4 results
Halozyme Therapeutics came out with a quarterly loss of $0.01 per share versus Wall Street's estimate of a loss of $0.02. This compares to earnings of $0.85 per share a year ago. This quarterly report represents an earnings surprise of 50%. Last quarter, it was expected that this biopharmaceutical company would post a loss of $0.23 per share when it actually produced a loss of $0.19. Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Halozyme posted revenue of $60.23 million for the quarter ended December 2018. "We have a broad enhanced pipeline with our partners," said Helen Torley, CEO of Halozyme in a conference call. "By the end of 2019, we project this will include three products in Phase 3 clinical testing and nine products in Phase 1 clinical testing. With those key takeaways, let me provide some additional details on our recent progress and results. Earlier this month, we announced a new collaboration with argenx, a development-stage biotechnology company with a focus on severe autoimmune diseases and other therapeutic areas."
HALO saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for HALO moved out of overbought territory on November 28, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 58 similar instances where the indicator exited the overbought zone. In of the 58 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for HALO moved out of overbought territory on November 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HALO broke above its upper Bollinger Band on November 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2025. You may want to consider a long position or call options on HALO as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HALO just turned positive on October 24, 2025. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .
HALO moved above its 50-day moving average on November 21, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HALO crossed bullishly above the 50-day moving average on November 20, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 303 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.667) is normal, around the industry mean (27.316). P/E Ratio (15.063) is within average values for comparable stocks, (52.494). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.898). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (7.215) is also within normal values, averaging (323.945).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology
Advertisement